Newer Blood Thinner May Improve Outcomes for Heart Attack Survivors

March 14, 2015 4:00 PM

2 0

SATURDAY, March 14, 2015 (HealthDay News) -- Long-term use of the newer anti-clotting drug Brilinta cut heart attack survivors' future risk of heart attack, stroke or heart-related death, a new study found.

The study was funded by Brilinta's maker, AstraZeneca, and was scheduled for presentation Saturday in San Diego at the annual meeting of the American College of Cardiology (ACC).

Also read: Deutsche Bank Posts Unexpected Profit on Lower Overhaul Costs

Read more

To category page